Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DA 3003-2, a selectively potent Cdc25 inhibitor, exhibits antiproliferative activity and holds potential for prostate cancer research. It induces cell cycle arrest at the G2/M phase and increases the expression of P-tyr 15 Cdc2.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | 35 days | $ 155.00 | |
5 mg | 35 days | $ 675.00 | |
10 mg | 35 days | $ 1,190.00 | |
25 mg | 35 days | $ 2,410.00 |
Description | DA 3003-2, a selectively potent Cdc25 inhibitor, exhibits antiproliferative activity and holds potential for prostate cancer research. It induces cell cycle arrest at the G2/M phase and increases the expression of P-tyr 15 Cdc2. |
In vivo | Pentigetide (1 mg ; four times daily)-treated patients showed a statistically significant greater reduction in the frequency (P = .004) and severity (P = .05) of total nasal symptom score (sneezing, nasal congestion, and rhinorrhea) and in the individual nasal symptom scores compared with placebo-treated patients.[1] |
Synonyms | NSC663285 |
Molecular Weight | 321.76 |
Formula | C15H16ClN3O3 |
CAS No. | 383907-47-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
DA 3003-2 383907-47-9 NSC 663285 NSC-663285 NSC663285 inhibitor inhibit